Search clinical trials for: BI 1021958 qd

Total 1439 results

Boehringer Ingelheim

Completed

Safety, Tolerability and Pharmacokinetics of Single Rising Inhaled Doses of BI 11054 CL Administered With the Respimat® in Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Completed

Safety, Tolerability and Pharmacokinetics of Multiple Rising Oral Doses of BI 44370 TA Tablets in Healthy Male and Female Volunteers

Healthy
Duke University

Completed

Early Detection of Lung Cancer Via Bi-plane Correlation Chest Imaging

Lung Cancer | Metastatic Cancer in the Lungs

United States
Boehringer Ingelheim

Completed

Utilization of HIV Drug Resistance Testing in Treatment Experienced Patients (UTILIZE Study)

HIV Infections

United States, Puerto Rico
Boehringer Ingelheim

Completed

A Study in Healthy People to Compare 2 Different Formulations of BI 1358894 Tablets Taken With or Without Food

Healthy

Germany
Boehringer Ingelheim

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses of BI 11634 Solution in Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Completed

A Study in Healthy Men to Test How Different Doses of BI 1815368 Are Tolerated and How BI 1815368 is Taken up in the Body With or Without Food

Healthy

Germany
Boehringer Ingelheim
Eli Lilly and Company

Completed

Linagliptin as Add on Therapy to Empagliflozin 10 mg or 25 mg With Background Metformin in Patient With Type 2 Diabetes

Diabetes Mellitus, Type 2

United States, Argentina, Australia, Canada, El Salvador, Germany, Italy, Portugal, Russian Federation, Spain, Ukraine
University of Leeds

Completed

Feasibility of Consumption of Nutritional Supplementation in Primary Ciliary Dyskinesia ((PCD))

Primary Ciliary Dyskinesia

United Kingdom
Shanghai Antengene Corporation Limited

Terminated

A Study of Evaluating the Safety and Efficacy of ATG-008 for Advanced Solid Tumors (BUNCH)

Advanced Solid Tumors

China
HK inno.N Corporation

Completed

Study to Confirm the Safety and Efficacy of CJ-12420 in Patients With Erosive Esophagitis

Erosive Esophagitis

Korea, Republic of
Boehringer Ingelheim

Completed

Safety, Tolerability and Pharmacokinetics of the Fixed Dose Combination of BI 1744 CL Plus BI 54903 XX Via Respimat® B Versus the Mono Products of BI 1744 CL Via Respimat® A and BI 54903 XX Via Respimat® B in Healthy Male and Female Volunteers

Healthy
Boehringer Ingelheim

Completed

Safety, Tolerability and Pharmacokinetics of the Fixed Dose Combination of BI 1744 CL Plus BI 54903 XX Via Respimat® B Versus the Free Combination of BI 1744 CL Via Respimat® A and BI 54903 XX Via Respimat® B in Healthy Male and Female Volunteers

Healthy
Boehringer Ingelheim

Completed

A Study in Healthy Men to Test How BI 1291583 is Processed in the Body

Healthy

Netherlands
Boston Medical Center
Boston University; National Institute on Drug Abuse (NIDA); RTI International

Completed

Assessing Screening Plus Brief Intervention's Resulting Efficacy (ASPIRE) to Stop Drug Use (ASPIRE)

Drug Abuse | Drug Usage | Drug Dependence

United States
Boehringer Ingelheim

Completed

Clinical Drug Trial in Healthy Male Subjects to Determine and Compare the Blood Concentrations of BI 144807 Following Administration as Oral Solution and Tablet Under Fasted and Fed Conditions

Healthy

Germany
Boehringer Ingelheim

Active, not recruiting

A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who Also Have Diabetes to Lose Weight (SYNCHRONIZE™-2)

Obesity | Diabetes Mellitus, Type 2

Spain, United States, Korea, Republic of, Belgium, Australia, China, Poland, Japan, Finland, Germany, Greece, Canada, Hungary, New Zealand, Sweden, United Kingdom, Netherlands, Czechia, Denmark
Boehringer Ingelheim

Completed

A Study to Test the Effect of Different Doses of Avenciguat (BI 685509) on Kidney Function in People With Chronic Kidney Disease

Chronic Kidney Disease

Spain, Canada, Australia, United States, Japan, Malaysia, United Kingdom, China, Mexico, Denmark, Russian Federation, Germany, Portugal, Hong Kong, Poland, Argentina, New Zealand, Sweden
Boehringer Ingelheim

Completed

A Study of BI 765128 in Patients With an Eye Condition Called Diabetic Macular Ischemia Who Have Received Laser Treatment (PARTRIDGE)

Diabetic Retinopathy

Spain, United Kingdom, United States, Netherlands, Australia, Latvia
Boehringer Ingelheim

Completed

A Study in Healthy Men to Test How Well Different Doses of BI 1819479 Are Tolerated

Healthy

Japan
Alkahest, Inc.

Completed

Evaluate the Therapeutic Effects and Safety of ALK4290 in Patients With Refractory Wet Age-Related Macular Degeneration

Wet Age-related Macular Degeneration

Hungary
Boehringer Ingelheim

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses of BI 14332 CL Powder in Healthy Male Subjects

Healthy
Boehringer Ingelheim

Completed

BI 2536 BS in Patients With Advanced Solid Tumours and Repeated Administration in Patients With Clinical Benefit

Neoplasms
Boehringer Ingelheim

Terminated

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 14332 CL as Tablet in Female and Male Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2
Boehringer Ingelheim

Completed

A Study in Healthy Men to Test How BI 730357 is Processed by the Body

Healthy

Netherlands
Boehringer Ingelheim

Completed

Metabolism and Pharmacokinetics of [14C]-BI 409306 After Administration as Oral Solution in Healthy Male Volunteers

Healthy

United Kingdom
VA Office of Research and Development

Completed

Effects of PPAR Ligands on Ectopic Fat Accumulation and Inflammation

Prediabetic State | Metabolic Syndrome X

United States
Boehringer Ingelheim

Recruiting

A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT)

Obesity

United States, Korea, Republic of, Belgium, Australia, United Kingdom, Italy, Mexico, Spain, Germany, Taiwan, Netherlands, Brazil, Hungary, Denmark, Canada, Austria, China, Poland, Finland, Greece, Hong Kong, Czechia, Portugal, Saudi... and more
Assiut University
WGEKHALEEL; AARMHUSSIEN

Recruiting

HFNC in Management of Bronchiectasis Exacerbation

Bronchiectasis

Egypt
Boehringer Ingelheim

Recruiting

A Study in People With Systemic Sclerosis to Test Whether Avenciguat (BI 685509) Has an Effect on Lung Function and Other Systemic Sclerosis Symptoms (VITALISScE™)

Scleroderma, Systemic

United States, Belgium, Korea, Republic of, Australia, China, Taiwan, Spain, Israel, Japan, Mexico, Turkey, Germany, Italy, Brazil, France, Singapore, India, Philippines, United Kingdom, Switzerland, Finland, Greece, New Zealand, Denmark and more
Boehringer Ingelheim

Recruiting

A Study to Determine How BI 907828 (Brigimadlin) is Taken up in the Tumor (Phase 0) and to Determine the Highest Dose of BI 907828 (Brigimadlin) That Could be Tolerated (Phase 1a) in Combination With Radiation Therapy in People With a Brain Tumor Called Glioblastoma

Glioblastoma

Belgium, Spain, United States
Universitat Jaume I

Not yet recruiting

Blended Treatment for Problem Gambling and Gambling Disorder Combining Group Sessions and Online Modules

Gambling Disorder | Problem Gambling

Spain
Boehringer Ingelheim

Completed

A Study to Test Whether Different Doses of BI 456906 Help People With Overweight or Obesity to Lose Weight

Obesity

Belgium, Australia, Sweden, United States, Canada, Germany, Korea, Republic of, China, Netherlands, New Zealand, United Kingdom, Poland
Boehringer Ingelheim

Completed

A Study in Healthy Men to Test How BI 456906 is Processed in the Body

Healthy

Netherlands
Boehringer Ingelheim

Completed

Phase I Dose Escalation of i.v. BI 836909 Monotherapy in Last Line Multiple Myeloma Patients

Multiple Myeloma

Germany, France
Boehringer Ingelheim

Completed

Relative Bioavailability of a Single Dose of BI 44370 Tablet During and Between Migraine Attacks

Migraine Disorders

Belgium, Germany
Stereotaxis

Terminated

MAGNET CRT Feasibility - Efficiency of LV Lead Placement Comparing Conventional vs. Magnetic Guidance

Cardiac Resynchronization Therapy

United States
AbbVie

No longer available

Expanded Access to Risankizumab

Crohn's Disease | Ulcerative Colitis (UC)
University of Reading
Danisco

Completed

A Study of a Prebiotic, a Probiotic and a Synbiotic Upon the Gut Microbiota and Immune Response of Healthy Volunteers (XOS)

Gut Microbiota | Immune Function | Bowel Function | Plasma Lipids

United Kingdom
William Beaumont Hospitals
Haines, David MD

Completed

Biventricular Pacing In Patients With Left Ventricular Dysfunction After Cardiovascular Surgery

Thoracic Surgery | Heart Failure, Congestive | Cardiomyopathy

United States
Eisai Inc.

Completed

BLOSSOM: Behavioral Modification and Lorcaserin Second Study for Obesity Management

Obesity

United States
Boehringer Ingelheim

Completed

To Investigate the Safety, Tolerability, Pharmacokinetics and the Relative Bioavailability of BI 1026706

Healthy

Germany
Boehringer Ingelheim

Completed

4 Week Treatment With Three Oral Doses of BI 10773 in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

Germany
Boehringer Ingelheim

Completed

Japanese Pegylated Interferon (PegIFN) Alfa-2b/Ribavirin (RBV) Combination Trial

Hepatitis C

Japan
vTv Therapeutics

Recruiting

Cadisegliatin as Adjunctive Therapy in Type 1 Diabetes (CATT1)

Diabetes Mellitus, Type 1

United States
Sichuan Haisco Pharmaceutical Group Co., Ltd

Completed

Efficacy and Safety of Polyene Phosphatidylcholine in Treatment of Patients With Acute Drug-induced Liver Injury

Acute Drug Induced Liver Injury

China
Boehringer Ingelheim

Completed

IFN-free Combination Therapy in HCV-infected Patients Treatment-naive:HCVerso1

Hepatitis C, Chronic

United States, Austria, Canada, France, Germany, Hungary, Ireland, Italy, Netherlands, Portugal, Romania, Russian Federation, Spain, United Kingdom
Boehringer Ingelheim

Completed

Single Rising Dose Study of BI 207127 NA in Healthy Male Asian Volunteers and Single Dose Study of BI 207127 NA in Healthy Male Caucasian Volunteers

Healthy

Korea, Republic of
Chong Kun Dang Pharmaceutical

Completed

Clinical Trial to Evaluate the Efficacy and Safety of D064 and D702 Combination Therapy Versus D064 or D702 Monotherapy

Essential Hypertension

Korea, Republic of
XenoPort, Inc.

Completed

An Efficacy and Safety Study of XP19986 in Subjects With Symptomatic GERD

Gastroesophageal Reflux

United States

3

Subscribe